BUZZ-Ardelyx jumps as Piper Sandler highlights strong Ibsrela uptake

Reuters01-09
BUZZ-<a href="https://laohu8.com/S/ARDX">Ardelyx</a> jumps as Piper Sandler highlights strong Ibsrela uptake

** Shares of biotech drug developer Ardelyx ARDX.O rise nearly 2% to $7.15 in premarket trading

** Piper Sandler upgrades stock rating to "overweight" from "neutral"; raises PT to $16 from $10, representing ~128.57% upside to stock's last close

** Cites stronger‑than‑expected momentum for Ibsrela, co's oral treatment for irritable bowel syndrome with constipation, following the company's latest update

** The brokerage said near‑term visibility has improved while management’s revised long‑term outlook pulls forward the product’s path to meaningful scale, which it views as achievable

** Eleven analysts rate the stock "strong buy" on average; median PT is $11 - data compiled by LSEG

** As of last close, ARDX is up ~31% in the past 12 months

(Reporting by Akriti Shah in Bengaluru)

((akriti.shah@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment